Head of the IP & Technology practice group Marleen van den Horst (J.D.) has more than 25 years of experience in complex, multi-jurisdictional patent litigation. She successfully represents clients in patent disputes in all fields of technology: mechanics, life sciences, chemistry and high-tech/telecoms. She is internationally renowned for her patent, regulatory and product liability work in life sciences. Marleen conducts patent/SPC litigation and advises regarding e.g. escitalopram, glatiramer acetate, zoledronate, rivastigmine pemetrexed, rituximab and on CRISPRCas9 technology. In the field of high tech/telecoms Marleen advises on European litigation strategy for enforcing (UMTS and LTE standard essential) patents and on FRAND-related issues and coordinates the preparation thereof. She is a frequent speaker on patent/SPC litigation at international conferences.